CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN chinese subjects

Acta Pharmacologica Sinica

Volumn 20, Issue 8, 1999, Pages 720-724

  Cai, Wei Min ^c   Chen, Bing ^b   Cai, Ming Hong ^b   Zhang, Yin Di ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^c NONE

Author keywords

Cytochrome P 450 CYP2D6; High pressure liquid chromatography; Mongoloid race; Pharmacokinetics; Phenotype; Propafenone; Stereoisomerism

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; PROPAFENONE;

AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENANTIOMER; ETHNOLOGY; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOGENETICS; PHENOTYPE; STEREOISOMERISM;

ADULT; ANTI-ARRHYTHMIA AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROPAFENONE; STEREOISOMERISM;

EID: 0032821368     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hii JT, Duff HJ, Burgess ED. Clinical pharmacokinetics of propafenone. Clin Pharmacokinet 1991; 21: 1-10.
2. Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, et al. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 1989; 79: 1068-76.
3. Volz M, Mitrovic V, Schlepper M. Steady-state plasma concentrations of propafenone-chirality and metabolism. Int J Clin Pharmacol Ther 1991; 32: 370-5.
4. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, et al. Polymorphism of propafenone metabolism and disposition in man: clinical pharmacokinetic consequences. Circulation 1987; 75: 785-91.
5. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [Published erratum appears in Clin Pharmacol Ther 1994; 55: 618]. Clin Pharmacol Ther 1992; 51: 388-97.
6. Cai WM, Chen B, Liu YX, Chu X. Dextromethorphan metabolic phenotyping in a Chinese population. Acta Pharmacol Sin 1997; 18: 411-4.
7. Chen B, Cai WM, Wan W. Determination of propafenone enantiomeric concentrations in human plasma by Stereoselective high performance liquid chromatography. Chin Pharm J 1998; 33: 516-9.
8. Yang YC, Chen G, Yuan L. A non-linear method and its program for calculating pharmacokinetic parameters. Acta Pharmacol Sin 1983; 4: 217-20.
9. Jonkers RE, Koopmans RP, Portier EJ, Boxtel CJ. Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. J Pharmacol Exp Ther 1991; 256: 959-66.
10. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57: 518-24.
11. Rudorfer MV, Lane EA, Chang WH, Zhang MD, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17: 433-40.
12. Horai Y, Nakano M, Ishizaki T, Ishikawa L, Zhou HH, Zhou BI, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese vesus mainland Chinese. Clin Pharmacol Ther 1989; 46: 198-207.
13. Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991; 49: 410-9.
14. Kuang TY, Lou YC, Tao P. Pharmacokinetics of propafenone and its relationship with debrisoquin and mephenytoin metabolism polymorphisms in healthy Chinese volunteers. Chin J Pharmacol Toxicol 1994; 8: 13-8.
15. Zhong DF, Wasng YQ, Wang AM. Stereoselective pharmacokinetic studies on the propafenone enantiomers. Chin J Clin Pharmacol 1997; 13: 82-7.